Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Market Cap $1.600B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 15.59pm 22/08/2025 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | $8.97 | Day High | $8.97 | Day Low | $8.81 | |||
| Daily Volume | 203843 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 2 | $8.81 | 741 | 2 | $8.88 | 741 | |
Directors & Senior Management
| Ms. Mary Stojcevski | Chief Financial Officer, Executive Director |
| Mr. Vladimir Mitnovetski | Chief Operating Officer, Executive Director |
| Mr. Ian Welch | Chief Information Officer, Director - Operations, Executive Director |
| Ms. Erin Mcmullen | Company Secretary |
| Ms. Fiona Tudor Brown | Non-Executive Director |
| Ms. Leanne Ralph | Non-Executive Independent Director |
| Ms. Kim Stewart-Smith | Non-Executive Independent Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
$8.86 |
Change
-0.110(1.23%) |
Mkt cap ! $1.600B | |||
| Open | High | Low | Value | Volume |
| $8.97 | $8.97 | $8.81 | $1.806M | 203.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 741 | $8.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $8.88 | 741 | 2 |
View Market Depth
| Last trade - 16.10pm 22/08/2025 (20 minute delay) ? |
|
|||||
|
Last
$8.84 |
Change
-0.110 ( 1.31 %) |
||||
| Open | High | Low | Volume | ||
| $8.94 | $8.94 | $8.82 | 38702 | ||
| Last updated 15.59pm 22/08/2025 ? | |||||
| DDR (ASX) Chart |
